Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714272 | 0.86 | TNKS (0.41) | ALDH1A1NPSR1MAPK14MAPK11MAPK13 | |
| SCHEMBL5738326 | 0.83 | NPC1 (0.46) | ALDH1A1NOTUMIDO1SMN1; SMN2CYP1A2 | |
| SCHEMBL4712870 | 0.81 | ALDH1A1 (0.45) | ALDH1A1NPSR1ADORA2AIDO1SMN1; SMN2 | |
| SCHEMBL4710873 | 0.81 | PIK3CG (0.43) | ALDH1A1LMNAMAPK14MAPK11MAPK13 | |
| SCHEMBL5739398 | 0.81 | IDO1 (0.45) | TDO2IKBKBALDH1A1LMNANPSR1 | |
| SCHEMBL4713814 | 0.79 | ADORA2A (0.50) | ALDH1A1ADORA2AADORA1MAPK14MAPK11 | |
| SCHEMBL4716460 | 0.77 | ALDH1A1 (0.50) | ALDH1A1ADORA2AMAPK14SMN1; SMN2 | |
| SCHEMBL5739682 | 0.76 | ALDH1A1 (0.53) | ALDH1A1LMNANPSR1ADORA2ASMN1; SMN2 | |
| SCHEMBL5247807 | 0.76 | JAK3 (0.43) | LMNAADORA2AADORA1IDO1 | |
| SCHEMBL4710870 | 0.76 | TRPA1 (0.42) | ALDH1A1NOTUMCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644371-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMA INC (US) | 2008-02-13 | — | — | EP | claimed |
| US-7132428-B2 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | claimed |
| EP-1644371-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005012301-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-10 | — | — | WO | claimed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | claimed |
| EP-1644371-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMA INC (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7132428-B2 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1644371-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005012301-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | PRKDC, MAP3K2, MAP3K20 | TDO2 3625/4885IKBKB 34/4885ALDH1A1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.